{
    "organizations": [],
    "uuid": "ddfbafb13f8beee96301cff651af61587c30788c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-promis-neurosciences-posts-q1-net/brief-promis-neurosciences-posts-q1-net-loss-of-1-6-million-idUSASC0A1RA",
    "ord_in_thread": 0,
    "title": "BRIEF-Promis Neurosciences Posts Q1 Net Loss Of $1.6 Million",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 11 (Reuters) - ProMIS Neurosciences Inc:\n* PROMIS NEUROSCIENCES ANNOUNCES FIRST QUARTER 2018 RESULTS\n* PROMIS NEUROSCIENCES INC - PLAN IS TO FURTHER ADVANCE ITS AD PORTFOLIO, WITH A FOCUS ON DEVELOPMENT OF PMN310 FOR CLINICAL TRIAL INITIATION IN 2019\n* PROMIS NEUROSCIENCES INC - NET LOSS FOR QUARTER WAS $1.6 MILLION VERSUS NET LOSS OF $1.4 MILLION Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-05-11T19:45:00.000+03:00",
    "crawled": "2018-05-12T17:34:01.013+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "promis",
        "neuroscience",
        "inc",
        "promis",
        "neuroscience",
        "announces",
        "first",
        "quarter",
        "result",
        "promis",
        "neuroscience",
        "inc",
        "plan",
        "advance",
        "ad",
        "portfolio",
        "focus",
        "development",
        "pmn310",
        "clinical",
        "trial",
        "initiation",
        "promis",
        "neuroscience",
        "inc",
        "net",
        "loss",
        "quarter",
        "million",
        "versus",
        "net",
        "loss",
        "million",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}